Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences has entered into a securities purchase agreement for a registered direct offering of 307,692 shares of common stock. The gross proceeds are about $2 million, and the closing is expected on or about August 24. Shares of the company are up nearly 18% at $6.10.

Jupiter Neurosciences is advancing its Phase 2a RESET trial of JOTROL in Parkinson's disease, with patient enrollment underway and topline data expected in the first quarter of 2027. The company's lead candidate is an oral, enhanced-bioavailability formulation of trans-resveratrol designed to address neuroinflammation, oxidative stress, and mitochondrial dysfunction. Jupiter reported approximately nine-fold higher plasma bioavailability than conventional resveratrol in a Phase 1 study of 24 patients, with measurable cerebrospinal-fluid exposure and no serious adverse events. The randomized, placebo-controlled Phase 2a trial is enrolling 30 patients and will evaluate safety, tolerability, pharmacokinetics, cerebrospinal fluid penetration, and inflammatory biomarkers alongside standard clinical assessments. Jupiter's market capitalization is approximately $5.0 million, compared with Parkinson's-focused peers ranging from roughly $76 million to more than $300 million.

Jupiter Neurosciences has signed a definitive licensing agreement with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented formulation of MDMA, in a deal valued at up to $100 million including milestones. The transaction transforms Jupiter into a dual clinical-stage CNS company, adding ALA-002 to its existing Phase II Parkinson's disease program for JOTROL, a proprietary enhanced bioavailability resveratrol formulation. Chairman and CEO Christer Rosén and President Alison Silva discussed the acquisition during a fireside chat hosted by IPO Edge, noting the primary indication for ALA-002, its addressable market size, and potential revenue relative to the acquisition cost. They also addressed the status of the Phase II Parkinson's trial, the evolving U.S. regulatory landscape for psychedelics, and key milestones across the company's portfolio.